PMID- 25779009
OWN - NLM
STAT- MEDLINE
DCOM- 20151221
LR  - 20201209
IS  - 1769-6690 (Electronic)
IS  - 0399-077X (Linking)
VI  - 45
IP  - 3
DP  - 2015 Mar
TI  - Bactericidal activity of 3 cutaneous/mucosal antiseptic solutions in the presence 
      of interfering substances: Improvement of the NF EN 13727 European Standard?
PG  - 89-94
LID - S0399-077X(15)00012-8 [pii]
LID - 10.1016/j.medmal.2015.01.006 [doi]
AB  - OBJECTIVE: There is no standard protocol for the evaluation of antiseptics used 
      for skin and mucous membranes in the presence of interfering substances. Our 
      objective was to suggest trial conditions adapted from the NF EN 13727 standard, 
      for the evaluation of antiseptics used in gynecology and dermatology. METHODS: 
      Three antiseptic solutions were tested in vitro: a chlorhexidine-benzalkonium 
      (CB) combination, a hexamidine-chlorhexidine-chlorocresol (HCC) combination, and 
      povidone iodine (P). The adaptation of trial conditions to the standard involved 
      choosing dilutions, solvent, and interfering substances. The activity of 
      solutions was assessed on the recommended strains at concentrations of 97% (pure 
      solution), 50%, and 10% (diluted solution), and 1%. A logarithmic reduction >/= 5 
      was expected after 60seconds of contact, to meet requirements of bactericidal 
      activity. RESULTS: HCC did not present any bactericidal activity except on P. 
      aeruginosa at a concentration of 97%. P was not bactericidal on E. hirae at any 
      concentration and on S. aureus at 97%. CB had the most homogeneous bactericidal 
      activity with a reduction>5 log on the 4 bacterial strains at concentrations of 
      97%, 50% and 10%. CONCLUSION: Adapting the NF EN 13727 standard allowed assessing 
      the 3 tested solutions: only CB was bactericidal in dirty conditions. This study 
      proved the possibility of validating antiseptic choice in vitro, in current 
      practice conditions, for adjunctive treatment of skin and mucous membranes 
      disorders, primarily of bacterial origin or with a potential of superinfection.
CI  - Copyright (c) 2015 Elsevier Masson SAS. All rights reserved.
FAU - Salvatico, S
AU  - Salvatico S
AD  - Fonderephar, 35, chemin des Maraichers, 31062 Toulouse cedex 9, France.
FAU - Feuillolay, C
AU  - Feuillolay C
AD  - Fonderephar, 35, chemin des Maraichers, 31062 Toulouse cedex 9, France.
FAU - Mas, Y
AU  - Mas Y
AD  - Laboratoire Innotech International, 22, avenue Aristide-Briand, 94110 Arcueil, 
      France.
FAU - Verriere, F
AU  - Verriere F
AD  - Laboratoire Innotech International, 22, avenue Aristide-Briand, 94110 Arcueil, 
      France.
FAU - Roques, C
AU  - Roques C
AD  - Fonderephar, 35, chemin des Maraichers, 31062 Toulouse cedex 9, France; 
      Laboratoire de genie chimique, UMR 5503, UFR pharmacie, universite de Toulouse, 
      35, chemin des Maraichers, 31062 Toulouse cedex 9, France. Electronic address: 
      ch.roques@wanadoo.fr.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150313
PL  - France
TA  - Med Mal Infect
JT  - Medecine et maladies infectieuses
JID - 0311416
RN  - 0 (Anti-Infective Agents, Local)
RN  - 0 (Benzalkonium Compounds)
RN  - 0 (Benzamidines)
RN  - 0 (Cresols)
RN  - 0 (Drug Combinations)
RN  - 0 (Inorganic Chemicals)
RN  - 0 (Solutions)
RN  - 27432CM55Q (Serum Albumin, Bovine)
RN  - 3483C2H13H (hexamidine)
RN  - 36W53O7109 (chlorocresol)
RN  - 85H0HZU99M (Povidone-Iodine)
RN  - MOR84MUD8E (chlorhexidine gluconate)
RN  - R4KO0DY52L (Chlorhexidine)
SB  - IM
MH  - Animals
MH  - Anti-Infective Agents, Local/*pharmacology
MH  - Benzalkonium Compounds/pharmacology
MH  - Benzamidines/pharmacology
MH  - Cattle
MH  - Chlorhexidine/analogs & derivatives/pharmacology
MH  - Cresols/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Drug Combinations
MH  - Drug Interactions
MH  - Enterococcus/drug effects
MH  - *Erythrocytes
MH  - Escherichia coli/drug effects
MH  - Europe
MH  - Hand Disinfection
MH  - Humans
MH  - Inorganic Chemicals/*pharmacology
MH  - Microbial Sensitivity Tests/*methods/standards
MH  - Mucous Membrane/microbiology
MH  - Osmolar Concentration
MH  - Povidone-Iodine/pharmacology
MH  - Pseudomonas aeruginosa/drug effects
MH  - Serum Albumin, Bovine/*pharmacology
MH  - Skin/microbiology
MH  - Solutions
MH  - Staphylococcus aureus/drug effects
OTO - NOTNLM
OT  - Antisepsie
OT  - Antisepsis
OT  - Benzalkonium
OT  - Chlorhexidine
OT  - Povidone iodine
OT  - Povidone iodee
EDAT- 2015/03/18 06:00
MHDA- 2015/12/22 06:00
CRDT- 2015/03/18 06:00
PHST- 2014/04/24 00:00 [received]
PHST- 2014/10/20 00:00 [revised]
PHST- 2015/01/14 00:00 [accepted]
PHST- 2015/03/18 06:00 [entrez]
PHST- 2015/03/18 06:00 [pubmed]
PHST- 2015/12/22 06:00 [medline]
AID - S0399-077X(15)00012-8 [pii]
AID - 10.1016/j.medmal.2015.01.006 [doi]
PST - ppublish
SO  - Med Mal Infect. 2015 Mar;45(3):89-94. doi: 10.1016/j.medmal.2015.01.006. Epub 
      2015 Mar 13.